

PRESS RELEASE

**Guerbet Board of Directors:
Appointment of a new director**

Villepinte, July 27, 2011

The Mixed General Meeting of Guerbet Shareholders, held on July 27, 2011 approved the appointment of a new director, **Mrs. Marion Barbier**.

Guerbet's Board of Directors decided, at its meeting held on June 9, 2011, under the chairmanship of Jean-Jacques Bertrand, to present the candidacy of Marion Barbier to shareholders.

Marion Barbier, a lawyer with a Master's degree in International Law, has been a partner at the Bird & Bird law firm since January 2000 and is specialized in commercial litigation and national and international arbitration.

Marion Barbier will bring to the Board her experience in the fields of industrial risk prevention and management, in particular in the telecommunications, Internet, IT and health sectors.

Marion Barbier is a member of the French Private International Law Committee. She is also an IFOMENE-certified mediator and a member of the European Mediators' Association.

A member of the Guerbet family, Marion Barbier holds 50 shares in the Guerbet company.

Members of the Board of Directors:

- Jean-Jacques Bertrand*, Chairman and CEO
- Marion Barbier
- Jacques Biot*, Chairman and CEO of JNB – Développement SA
- Vincent Dagommer, Head of Industrial Control, Europe at Novartis (OTC business)
- Olivier Guerbet, Senior Manager at SAS KEOSYS, Managing Director of ADS (sarl)
- Marie-Claire Janailhac-Fritsch*, consultant to the cosmetics industry and member of the French Institute of Directors (IFA)
- Christian Louvet

**Independent directors*

Dr. Michel Guerbet is the Honorary Chairman of the Guerbet company.

Six months after promulgation of the law on the feminization of major companies' management bodies, Guerbet's Board of Directors is now 28% female.

About Guerbet

Guerbet is the only pharmaceutical group totally dedicated to medical imaging on the world market. It has a full range of X-ray, MRI and nuclear medicine imaging products to enhance overall patient care. Its products facilitate diagnosis and the preparation of treatment strategies for major pathologies (cardiovascular diseases, cancers, inflammatory and degenerative diseases).

To discover new products and ensure its future development, Guerbet devotes significant resources to R&D every year: 210 staff and a sum equivalent to 11% of its sales. The programs on MRI and nuclear medicine modalities are central to Guerbet's research priorities.

Guerbet has a strong presence in Europe with a market share of 25% and is developing its presence in the United States, South America and Asia.

Guerbet, listed on the Euronext Paris Eurolist (compartment B), posted sales of €352 million in 2010 with a total headcount of 1300.

For more information on Guerbet, please go to www.guerbet.com.

Press contacts: Anne-Laure Delasalle, VP Communications & Image

Tel: + 33 (0)1 45 91 50 03

anne-laure.delasalle@guerbet-group.com